References
- Sundaram M., Kavookjian J., Patrick J. H., Miller L. A., Madhavan S. S., Scott V. G. Quality of life, health status and clinical outcomes in Type 2 diabetes patients. Qual Life Res 2007; 16: 165–77
- Bhosle M. J., Kulkarni A., Feldman S. R., Balkrishnan R. Quality of life in patients with psoriasis. Health Qual Life Outcomes 2006; 4: 35
- Brubaker L., Chapple C., Coyne K. S., Kopp Z. Patient‐reported outcomes in overactive bladder: importance for determining clinical effectiveness of treatment. Urology 2006; 68(2 suppl)3–8
- Coyne K. S., Matza L. S., Thompson C., Jumadilova Z., Bavendam T. The responsiveness of the OAB‐q among OAB patient subgroups. Neurourol Urodyn 2006; 26: 196–203
- Solish N., Benohanian A., Kowalski J. W., on behalf of the Canadian Dermatology Study Group on Health‐Related Quality of Life in Primary Axillary Hyperhidrosis. Prospective open‐label study of botulinum toxin type A in patients with axillary hyperhidrosis: effects on functional impairment and quality of life. Dermatol Surg 2005; 31: 405–13
- Khullar V., Chapple C., Gabriel Z., Dooley J. A. The effects of antimuscarinics on health‐related quality of life in overactive bladder: a systematic review and meta‐analysis. Urology 2006; 68(2 suppl)38–40
- Carruthers J. A., Lowe N. J., Menter M. A., Gibson J., Nordquist M., Mordaunt J., , for the BOTOX Glabellar Lines I Study Group, et al. A multicenter, double‐blind, randomized, placebo‐controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. J Am Acad Dermatol 2002; 46: 840–9
- Carruthers A., Carruthers J. Prospective, double‐blind, randomized, parallel‐group, dose‐ranging study of botulinum toxin type A in men with glabellar rhytids. Dermatol Surg 2005; 31: 1297–303
- Ascher B., Zakine B., Kestemont P., Baspeyras M., Bougara A., Santini J. A multicenter, randomized, double‐blind, placebo‐controlled study of efficacy and safety of 3 doses of botulinum toxin A in the treatment of glabellar lines. J Am Acad Dermatol 2004; 51: 223–33
- Carruthers J. D., Lowe N. J., Menter M. A., Gibson J., Eadie N., for the Botox Glabellar Lines II Study Group. Double‐blind, placebo‐controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar lines. Plast Reconstr Surg 2003; 112: 1089–98
- Finn J. C., Cox S. E., Earl M. L. Social implications of hyperfunctional facial lines. Dermatol Surg 2003; 29: 450–5
- Coté T. R., Mohan A. K., Polder J. A., Walton M. K., Braun M. M. Botulinum toxin type A injections: adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases. J Am Acad Dermatol 2005; 53: 407–15
- Carruthers A., Carruthers J. Long‐term safety of cosmetic botulinum toxin type A: a review. Dermatol Surg Submitted
- Sommer B., Zschocke I., Bergfeld D., Sattler G., Augustin M. Satisfaction of patients after treatment with botulinum toxin for dynamic facial lines. Dermatol Surg 2003; 29: 456–60
- Cox S. E., Finn J. C., Stetler L., Mackowiak J., Kowalski J. W. Development of the Facial Lines Treatment Satisfaction Questionnaire and initial results for botulinum toxin type A‐treated patients. Dermatol Surg 2003; 29: 444–9
- Beer K. R. Comparative evaluation of the safety and efficacy of botulinum toxin type A and topical creams for treating moderate‐to‐severe glabellar rhytids. Dermatol Surg 2006; 32: 184–97
- Carruthers A., Carruthers J., Dessain A. S. Preliminary results with the Facial Lines Outcomes (FLO) questionnaire in the treatment of multiple upper facial rhytids with botulinum toxin type A: results from a single‐center, dose‐comparison, pilot study. J Am Acad Dermatol, Submitted
- Carruthers J., Carruthers A. Botulinum toxin type A treatment of multiple upper facial sites: patient‐reported outcomes. Dermatol Surg 2007; 33(special issue)S10–17
- Fagien S., Cox S. E., Finn J. C., Werschler W. P., Kowalski J. W. Patient‐reported outcomes with botulinum toxin type A treatment of glabellar rhytids: a double‐blind, randomized, placebo‐controlled study. Dermatol Surg 2007; 33(special issue)S2–9
- Finzi E., Wasserman E. Treatment of depression with botulinum toxin A: a case series. Dermatol Surg 2006; 32: 645–50